Peeling Back the Layers of the Bleomycin Model of Lung Fibrosis: Lessons Learned, Factors to Consider, and Future Directions

Patricia Brazee; Nancy Allen; Rachel Knipe; Elizabeth F. Redente; Claude Jourdan Le Saux

doi:10.1055/a-2649-9402

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med
DOI: 10.1055/a-2649-9402

Review Article

Peeling Back the Layers of the Bleomycin Model of Lung Fibrosis: Lessons Learned, Factors to Consider, and Future Directions

Authors

Patricia Brazee

¹Division of Pulmonary and Critical Care Medicine, Department of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, Massachusetts
Nancy Allen

²Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, California
Rachel Knipe

¹Division of Pulmonary and Critical Care Medicine, Department of Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, Massachusetts
Elizabeth F. Redente

³Division of Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colorado
Claude Jourdan Le Saux

²Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, California

Abstract

Bleomycin-induced lung injury remains the most widely used and well-characterized experimental model for studying pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). This review provides a comprehensive analysis of the bleomycin model's utility, phases, variability, and translational relevance. Bleomycin administration in rodents induces acute epithelial injury followed by inflammation, fibroblast activation, extracellular matrix deposition, and eventual fibrosis. The model progresses through defined stages, acute inflammation (days 1–7), fibrogenesis (days 7–28), and in most cases, spontaneous resolution (days 42–63), making it suitable for understanding temporal aspects of fibrosis and repair, the cell populations involved, and the signaling mechanisms involved. Despite its advantages, the single-dose model lacks key features of human IPF, including persistent fibrosis, honeycomb cysts, and fibroblastic foci. Repetitive dosing and the use of aged mice have improved chronicity and recapitulation of progressive disease and observation of the expansion of aberrant epithelial cell populations in simple cyst structures. This review discusses route-specific effects, strain and sex susceptibilities, and the growing role of microbiome and genetic background in influencing fibrosis outcomes. It also highlights cellular responses across epithelial cell populations, fibroblasts, endothelial cells, and immune cell populations. Although limitations exist in this model—such as reversibility and incomplete modeling of human pathology—bleomycin remains invaluable for mechanistic studies and preclinical drug screening. Importantly, all FDA-approved antifibrotic drugs demonstrated efficacy in bleomycin models prior to clinical success. The review advocates for careful model selection, incorporation of persistent fibrosis models, and parallel use of human-relevant systems to enhance translational relevance in pulmonary fibrosis research.

Keywords

mouse model - pulmonary fibrosis - bleomycin

Full Text

References

References
1 Allawzi A, Elajaili H, Redente EF, Nozik-Grayck E. Oxidative toxicology of bleomycin: role of the extracellular redox environment. Curr Opin Toxicol 2019; 13: 68-73
2 Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol 2006; 33 (01) 98-105
3 Jenkins RG, Moore BB, Chambers RC. et al; ATS Assembly on Respiratory Cell and Molecular Biology. An official American Thoracic Society workshop report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis. Am J Respir Cell Mol Biol 2017; 56 (05) 667-679
4 Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. Int J Biochem Cell Biol 2008; 40 (03) 362-382
5 Liu T, De Los Santos FG, Phan SH. The bleomycin model of pulmonary fibrosis. Methods Mol Biol 2017; 1627: 27-42
6 B Moore B, Lawson WE, Oury TD, Sisson TH, Raghavendran K, Hogaboam CM. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol 2013; 49 (02) 167-179
7 Kolb P, Upagupta C, Vierhout M. et al. The importance of interventional timing in the bleomycin model of pulmonary fibrosis. Eur Respir J 2020; 55 (06) 1901105
8 Adamson IY, Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 1974; 77 (02) 185-197
9 Jones AW, Reeve NL. Ultrastructural study of bleomycin-induced pulmonary changes in mice. J Pathol 1978; 124 (04) 227-233
10 Adamson IY. Pulmonary toxicity of bleomycin. Environ Health Perspect 1976; 16: 119-126
11 Redente EF, Keith RC, Janssen W. et al. Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages. Am J Respir Cell Mol Biol 2014; 50 (04) 825-837
12 Bordag N, Biasin V, Schnoegl D. et al. Machine learning analysis of the bleomycin mouse model reveals the compartmental and temporal inflammatory pulmonary fingerprint. iScience 2020; 23 (12) 101819
13 Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 2002; 83 (03) 111-119
14 Redente EF, Chakraborty S, Sajuthi S. et al. Loss of Fas signaling in fibroblasts impairs homeostatic fibrosis resolution and promotes persistent pulmonary fibrosis. JCI Insight 2020; 6 (01) e141618
15 Tighe RM, Redente EF, Yu YR. et al. Improving the quality and reproducibility of flow cytometry in the lung. An official American Thoracic Society workshop report. Am J Respir Cell Mol Biol 2019; 61 (02) 150-161
16 Misharin AV, Morales-Nebreda L, Reyfman PA. et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J Exp Med 2017; 214 (08) 2387-2404
17 McCubbrey AL, Barthel L, Mohning MP. et al. Deletion of c-FLIP from CD11b^hi macrophages prevents development of bleomycin-induced lung fibrosis. Am J Respir Cell Mol Biol 2018; 58 (01) 66-78
18 King EM, Zhao Y, Moore CM. et al. Gpnmb and Spp1 mark a conserved macrophage injury response masking fibrosis-specific programming in the lung. JCI Insight 2024; 9 (24) e182700
19 Aran D, Looney AP, Liu L. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol 2019; 20 (02) 163-172
20 Watanabe S, Alexander M, Misharin AV, Budinger GRS. The role of macrophages in the resolution of inflammation. J Clin Invest 2019; 129 (07) 2619-2628
21 Gibbons MA, MacKinnon AC, Ramachandran P. et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med 2011; 184 (05) 569-581
22 Li R, Bernau K, Sandbo N, Gu J, Preissl S, Sun X. Pdgfra marks a cellular lineage with distinct contributions to myofibroblasts in lung maturation and injury response. eLife 2018; 7: e36865
23 Brass DM, Yang IV, Kennedy MP. et al. Fibroproliferation in LPS-induced airway remodeling and bleomycin-induced fibrosis share common patterns of gene expression. Immunogenetics 2008; 60 (07) 353-369
24 Xie T, Wang Y, Deng N. et al. Single-cell deconvolution of fibroblast heterogeneity in mouse pulmonary fibrosis. Cell Rep 2018; 22 (13) 3625-3640
25 Tsukui T, Wolters PJ, Sheppard D. Alveolar fibroblast lineage orchestrates lung inflammation and fibrosis. Nature 2024; 631 (8021) 627-634
26 Tsukui T, Sun KH, Wetter JB. et al. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat Commun 2020; 11 (01) 1920
27 Yunt ZX, Mohning MP, Barthel L. et al. Kinetics of the angiogenic response in lung endothelium following acute inflammatory injury with bleomycin. Exp Lung Res 2014; 40 (08) 415-425
28 Gilhodes JC, Julé Y, Kreuz S, Stierstorfer B, Stiller D, Wollin L. Quantification of pulmonary fibrosis in a bleomycin mouse model using automated histological image analysis. PLoS One 2017; 12 (01) e0170561
29 Dobrinskikh E, Estrella AM, Hennessy CE. et al. Genes, other than Muc5b, play a role in bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2021; 321 (02) L440-L450
30 Redente EF, Kopf KW, Bahadur AN, Robichaud A, Lundblad LK, McDonald LT. Application-specific approaches to MicroCT for evaluation of mouse models of pulmonary disease. PLoS One 2023; 18 (02) e0281452
31 El Agha E, Moiseenko A, Kheirollahi V. et al. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem Cell 2017; 20 (04) 571
32 Hecker L, Logsdon NJ, Kurundkar D. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med 2014; 6 (231) 231ra47
33 Redente EF, Jacobsen KM, Solomon JJ. et al. Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol 2011; 301 (04) L510-L518
34 Stout-Delgado HW, Cho SJ, Chu SG. et al. Age-dependent susceptibility to pulmonary fibrosis is associated with NLRP3 inflammasome activation. Am J Respir Cell Mol Biol 2016; 55 (02) 252-263
35 Xu J, Gonzalez ET, Iyer SS. et al. Use of senescence-accelerated mouse model in bleomycin-induced lung injury suggests that bone marrow-derived cells can alter the outcome of lung injury in aged mice. J Gerontol A Biol Sci Med Sci 2009; 64 (07) 731-739
36 Podolsky MJ, Yang CD, Valenzuela CL. et al. Age-dependent regulation of cell-mediated collagen turnover. JCI Insight 2020; 5 (10) e137519
37 Weckerle J, Mayr CH, Fundel-Clemens K. et al. Transcriptomic and proteomic changes driving pulmonary fibrosis resolution in young and old mice. Am J Respir Cell Mol Biol 2023; 69 (04) 422-440
38 Degryse AL, Tanjore H, Xu XC. et al. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010; 299 (04) L442-L452
39 Redente EF, Black BP, Backos DS. et al. Persistent, progressive pulmonary fibrosis and epithelial remodeling in mice. Am J Respir Cell Mol Biol 2021; 64 (06) 669-676
40 Cooley JC, Javkhlan N, Wilson JA. et al. Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis. JCI Insight 2023; 8 (03) e163762
41 Gul A, Yang F, Xie C. et al. Pulmonary fibrosis model of mice induced by different administration methods of bleomycin. BMC Pulm Med 2023; 23 (01) 91
42 Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005; 33 (01) 9-13
43 Walters DM, Kleeberger SR. Mouse models of bleomycin-induced pulmonary fibrosis. Curr Protocols Pharmacol 2008; Chapter 5: Unit 5.46
44 Seo Y, Qiu L, Magnen M. et al. Optimizing anesthesia and delivery approaches for dosing into lungs of mice. Am J Physiol Lung Cell Mol Physiol 2023; 325 (02) L262-L269
45 Nieuw Amerongen AV, Oderkerk CH, Veerman EC. Influence of phytate on the adsorption of human salivary mucins onto hydroxyapatite. J Biol Buccale 1988; 16 (04) 203-208
46 Egger C, Cannet C, Gérard C. et al. Administration of bleomycin via the oropharyngeal aspiration route leads to sustained lung fibrosis in mice and rats as quantified by UTE-MRI and histology. PLoS One 2013; 8 (05) e63432
47 Cao Z, Lis R, Ginsberg M. et al. Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis. Nat Med 2016; 22 (02) 154-162
48 Headley L, Bi W, Wilson C. et al. Low-dose administration of bleomycin leads to early alterations in lung mechanics. Exp Physiol 2018; 103 (12) 1692-1703
49 Lazo JS, Humphreys CJ. Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity. Proc Natl Acad Sci U S A 1983; 80 (10) 3064-3068
50 Liang M, Lv J, Zou L. et al. A modified murine model of systemic sclerosis: bleomycin given by pump infusion induced skin and pulmonary inflammation and fibrosis. Lab Invest 2015; 95 (03) 342-350
51 Harrison Jr JH, Lazo JS. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther 1987; 243 (03) 1185-1194
52 Shea BS, Brooks SF, Fontaine BA, Chun J, Luster AD, Tager AM. Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol 2010; 43 (06) 662-673
53 Shea BS, Probst CK, Brazee PL. et al. Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis. JCI Insight 2017; 2 (09) e86608
54 Gendron DR, Lemay AM, Lecours PB. et al. FTY720 promotes pulmonary fibrosis when administered during the remodelling phase following a bleomycin-induced lung injury. Pulm Pharmacol Ther 2017; 44: 50-56
55 Grandi A, Ferrini E, Zoboli M. et al. A mouse model of progressive lung fibrosis with cutaneous involvement induced by a combination of oropharyngeal and osmotic minipump bleomycin delivery. Am J Physiol Lung Cell Mol Physiol 2024; 326 (06) L736-L753
56 Schrier DJ, Kunkel RG, Phan SH. The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis 1983; 127 (01) 63-66
57 Voltz JW, Card JW, Carey MA. et al. Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2008; 39 (01) 45-52
58 Lamichhane R, Patial S, Saini Y. Higher susceptibility of males to bleomycin-induced pulmonary inflammation is associated with sex-specific transcriptomic differences in myeloid cells. Toxicol Appl Pharmacol 2022; 454: 116228
59 Raslan AA, Pham TX, Lee J. et al. Lung injury-induced activated endothelial cell states persist in aging-associated progressive fibrosis. Nat Commun 2024; 15 (01) 5449
60 Klee S, Picart-Armada S, Wenger K. et al. Transcriptomic and proteomic profiling of young and old mice in the bleomycin model reveals high similarity. Am J Physiol Lung Cell Mol Physiol 2023; 324 (03) L245-L258
61 Chioma OS, Mallott EK, Chapman A. et al. Gut microbiota modulates lung fibrosis severity following acute lung injury in mice. Commun Biol 2022; 5 (01) 1401
62 Yoon YM, Hrusch CL, Fei N. et al. Gut microbiota modulates bleomycin-induced acute lung injury response in mice. Respir Res 2022; 23 (01) 337
63 O'Dwyer DN, Ashley SL, Gurczynski SJ. et al. Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. Am J Respir Crit Care Med 2019; 199 (09) 1127-1138
64 Yang D, Chen X, Wang J. et al. Dysregulated lung commensal bacteria drive interleukin-17B production to promote pulmonary fibrosis through their outer membrane vesicles. Immunity 2019; 50 (03) 692-706.e7
65 Wuyts WA, Willems S, Vos R. et al. Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model. Exp Lung Res 2010; 36 (10) 602-614
66 Rudders RA, Hensley GT. Bleomycin pulmonary toxicity. Chest 1973; 63 (04) 627-628
67 Usuki J, Fukuda Y. Evolution of three patterns of intra-alveolar fibrosis produced by bleomycin in rats. Pathol Int 1995; 45 (08) 552-564
68 Munger JS, Huang X, Kawakatsu H. et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96 (03) 319-328
69 Bauer Y, Tedrow J, de Bernard S. et al. A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2015; 52 (02) 217-231
70 Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294 (02) L152-L160
71 Borzone G, Moreno R, Urrea R, Meneses M, Oyarzún M, Lisboa C. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 163 (07) 1648-1653
72 Limjunyawong N, Mitzner W, Horton MR. A mouse model of chronic idiopathic pulmonary fibrosis. Physiol Rep 2014; 2 (02) e00249
73 Raghu G, Anstrom KJ, King Jr TE, Lasky JA, Martinez FJ. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366 (21) 1968-1977
74 Song X, Yu W, Guo F. Pirfenidone suppresses bleomycin-induced pulmonary fibrosis and periostin expression in rats. Exp Ther Med 2018; 16 (03) 1800-1806
75 King Jr TE, Bradford WZ, Castro-Bernardini S. et al; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22) 2083-2092
76 Richeldi L, du Bois RM, Raghu G. et al; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22) 2071-2082
77 Kathiriya JJ, Wang C, Zhou M. et al. Human alveolar type 2 epithelium transdifferentiates into metaplastic KRT5⁺ basal cells. Nat Cell Biol 2022; 24 (01) 10-23
78 Xu Y, Mizuno T, Sridharan A. et al. Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis. JCI Insight 2016; 1 (20) e90558
79 Parimon T, Chen P, Stripp BR. et al. Senescence of alveolar epithelial progenitor cells: a critical driver of lung fibrosis. Am J Physiol Cell Physiol 2023; 325 (02) C483-C495
80 Desai TJ, Brownfield DG, Krasnow MA. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 2014; 507 (7491) 190-194
81 Miyata R, Hasegawa K, Menju T. et al. Lung fibrogenic microenvironment in mouse reconstitutes human alveolar structure and lung tumor. iScience 2022; 25 (09) 104912
82 Wang F, Ting C, Riemondy KA. et al. Regulation of epithelial transitional states in murine and human pulmonary fibrosis. J Clin Invest 2023; 133 (22) e165612
83 Chapman HA. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu Rev Physiol 2011; 73: 413-435
84 Thamsen M, Ghosh R, Auyeung VC. et al. Small molecule inhibition of IRE1α kinase/RNase has anti-fibrotic effects in the lung. PLoS One 2019; 14 (01) e0209824
85 Auyeung VC, Downey MS, Thamsen M. et al. IRE1α drives lung epithelial progenitor dysfunction to establish a niche for pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2022; 322 (04) L564-L580
86 Katzen J, Wagner BD, Venosa A. et al. An SFTPC BRICHOS mutant links epithelial ER stress and spontaneous lung fibrosis. JCI Insight 2019; 4 (06) e126125
87 Zhao M, Wang L, Wang M. et al. Targeting fibrosis, mechanisms and clinical trials. Signal Transduct Target Ther 2022; 7 (01) 206
88 Sisson TH, Mendez M, Choi K. et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 2010; 181 (03) 254-263
89 McCall AS, Gutor S, Tanjore H. et al. Hypoxia-inducible factor 2 regulates alveolar regeneration after repetitive injury in three-dimensional cellular and in vivo models. Sci Transl Med 2025; 17 (780) eadk8623
90 Garcia O, Hiatt MJ, Lundin A. et al. Targeted type 2 alveolar cell depletion. A dynamic functional model for lung injury repair. Am J Respir Cell Mol Biol 2016; 54 (03) 319-330
91 Nureki SI, Tomer Y, Venosa A. et al. Expression of mutant Sftpc in murine alveolar epithelia drives spontaneous lung fibrosis. J Clin Invest 2018; 128 (09) 4008-4024
92 Povedano JM, Martinez P, Flores JM, Mulero F, Blasco MA. Mice with pulmonary fibrosis driven by telomere dysfunction. Cell Rep 2015; 12 (02) 286-299
93 Mei Q, Liu Z, Zuo H, Yang Z, Qu J. Idiopathic pulmonary fibrosis: an update on pathogenesis. Front Pharmacol 2022; 12: 797292
94 Li X, Zhang H, Soledad-Conrad V, Zhuang J, Uhal BD. Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am J Physiol Lung Cell Mol Physiol 2003; 284 (03) L501-L507
95 Drakopanagiotakis F, Xifteri A, Polychronopoulos V, Bouros D. Apoptosis in lung injury and fibrosis. Eur Respir J 2008; 32 (06) 1631-1638
96 Lawson WE, Polosukhin VV, Stathopoulos GT. et al. Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin. Am J Pathol 2005; 167 (05) 1267-1277
97 Aoshiba K, Tsuji T, Nagai A. Bleomycin induces cellular senescence in alveolar epithelial cells. Eur Respir J 2003; 22 (03) 436-443
98 Hewlett JC, Kropski JA, Blackwell TS. Idiopathic pulmonary fibrosis: epithelial-mesenchymal interactions and emerging therapeutic targets. Matrix Biol 2018; 71-72: 112-127
99 Mercer PF, Johns RH, Scotton CJ. et al. Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179 (05) 414-425
100 Yamada Z, Nishio J, Motomura K. et al. Senescence of alveolar epithelial cells impacts initiation and chronic phases of murine fibrosing interstitial lung disease. Front Immunol 2022; 13: 935114
101 Kadur Lakshminarasimha Murthy P, Sontake V, Tata A. et al. Human distal lung maps and lineage hierarchies reveal a bipotent progenitor. Nature 2022; 604 (7904) 111-119
102 Tashiro J, Rubio GA, Limper AH. et al. Exploring animal models that resemble idiopathic pulmonary fibrosis. Front Med (Lausanne) 2017; 4: 118
103 Vats A, Chaturvedi P. The regenerative power of stem cells: treating bleomycin-induced lung fibrosis. Stem Cells Cloning 2023; 16: 43-59
104 Habermann AC, Gutierrez AJ, Bui LT. et al. Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis. Sci Adv 2020; 6 (28) eaba1972
105 Fang Y, Chung SSW, Xu L. et al. RUNX2 promotes fibrosis via an alveolar-to-pathological fibroblast transition. Nature 2025; 640 (8057) 221-230
106 Li Q, Wang Y, Ji L. et al. Cellular and molecular mechanisms of fibrosis and resolution in bleomycin-induced pulmonary fibrosis mouse model revealed by spatial transcriptome analysis. Heliyon 2023; 9 (12) e22461
107 Lingampally A, Truchi M, Mauduit O. et al. Evidence for a lipofibroblast-to-Cthrc1 ⁺ myofibroblast reversible switch during the development and resolution of lung fibrosis in young mice. Eur Respir J 2025; 65 (02) 2300482
108 Tan Q, Link PA, Meridew JA. et al. Spontaneous lung fibrosis resolution reveals novel antifibrotic regulators. Am J Respir Cell Mol Biol 2021; 64 (04) 453-464
109 Frangogiannis NG. Fibroblast-extracellular matrix interactions in tissue fibrosis. Curr Pathobiol Rep 2016; 4 (01) 11-18
110 Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol 2014; 5: 123
111 Tan C, Jiang M, Wong SS. et al. Soluble Thy-1 reverses lung fibrosis via its integrin-binding motif. JCI Insight 2019; 4 (21) e131152
112 Zhou Y, Huang X, Hecker L. et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 2013; 123 (03) 1096-1108
113 Hagimoto N, Kuwano K, Inoshima I. et al. TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J Immunol 2002; 168 (12) 6470-6478
114 Schiller HB, Fernandez IE, Burgstaller G. et al. Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair. Mol Syst Biol 2015; 11 (07) 819
115 Hinz B, Lagares D. Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases. Nat Rev Rheumatol 2020; 16 (01) 11-31
116 Liu X, Wong SS, Taype CA. et al. Thy-1 interaction with Fas in lipid rafts regulates fibroblast apoptosis and lung injury resolution. Lab Invest 2017; 97 (03) 256-267
117 Schafer MJ, White TA, Iijima K. et al. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun 2017; 8: 14532
118 Kato K, Logsdon NJ, Shin YJ. et al. Impaired myofibroblast dedifferentiation contributes to nonresolving fibrosis in aging. Am J Respir Cell Mol Biol 2020; 62 (05) 633-644
119 Atabai K, Yang CD, Podolsky MJ. You say you want a resolution (of fibrosis). Am J Respir Cell Mol Biol 2020; 63 (04) 424-435
120 Lingampally A, Truchi M, Shi X. et al. Unraveling alveolar fibroblast and activated myofibroblast heterogeneity and differentiation trajectories during lung fibrosis development and resolution in young and old mice. Aging Cell 2025; 24 (05) e14503
121 Kato S, Inui N, Hakamata A. et al. Changes in pulmonary endothelial cell properties during bleomycin-induced pulmonary fibrosis. Respir Res 2018; 19 (01) 127
122 Strunz M, Simon LM, Ansari M. et al. Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis. Nat Commun 2020; 11 (01) 3559
123 Murray LA, Habiel DM, Hohmann M. et al. Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. JCI Insight 2017; 2 (16) e92192
124 Baluk P, Naikawadi RP, Kim S. et al. Lymphatic proliferation ameliorates pulmonary fibrosis after lung injury. Am J Pathol 2020; 190 (12) 2355-2375
125 Caporarello N, Meridew JA, Aravamudhan A. et al. Vascular dysfunction in aged mice contributes to persistent lung fibrosis. Aging Cell 2020; 19 (08) e13196
126 Caporarello N, Lee J, Pham TX. et al. Dysfunctional ERG signaling drives pulmonary vascular aging and persistent fibrosis. Nat Commun 2022; 13 (01) 4170
127 Tager AM, LaCamera P, Shea BS. et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008; 14 (01) 45-54
128 Knipe RS, Spinney JJ, Abe EA. et al. Endothelial-specific loss of sphingosine-1-phosphate receptor 1 increases vascular permeability and exacerbates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2022; 66 (01) 38-52
129 Adams TS, Schupp JC, Poli S. et al. Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. Sci Adv 2020; 6 (28) eaba1983
130 Ji WJ, Ma YQ, Zhou X. et al. Temporal and spatial characterization of mononuclear phagocytes in circulating, lung alveolar and interstitial compartments in a mouse model of bleomycin-induced pulmonary injury. J Immunol Methods 2014; 403 (1-2): 7-16
131 Gasse P, Mary C, Guenon I. et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 2007; 117 (12) 3786-3799
132 Gasse P, Riteau N, Charron S. et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009; 179 (10) 903-913
133 Griffith JW, Faustino LD, Cottrell VI. et al. Regulatory T cell-derived IL-1Ra suppresses the innate response to respiratory viral infection. Nat Immunol 2023; 24 (12) 2091-2107
134 Cohen ML, Brumwell AN, Ho TC. et al. A fibroblast-dependent TGF-β1/sFRP2 noncanonical Wnt signaling axis promotes epithelial metaplasia in idiopathic pulmonary fibrosis. J Clin Invest 2024; 134 (18) e174598
135 Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King Jr TE. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008; 133 (01) 226-232
136 Moore BB, Paine III R, Christensen PJ. et al. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 2001; 167 (08) 4368-4377
137 Ucero AC, Bakiri L, Roediger B. et al. Fra-2-expressing macrophages promote lung fibrosis in mice. J Clin Invest 2019; 129 (08) 3293-3309
138 Lv J, Gao H, Ma J. et al. Dynamic atlas of immune cells reveals multiple functional features of macrophages associated with progression of pulmonary fibrosis. Front Immunol 2023; 14: 1230266
139 Zhou Y, Peng H, Sun H. et al. Chitinase 3-like 1 suppresses injury and promotes fibroproliferative responses in mammalian lung fibrosis. Sci Transl Med 2014; 6 (240) 240ra76
140 Unterman A, Zhao AY, Neumark N. et al. Single-cell profiling reveals immune aberrations in progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2024; 210 (04) 484-496
141 Reyfman PA, Walter JM, Joshi N. et al. Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis. Am J Respir Crit Care Med 2019; 199 (12) 1517-1536
142 Matsuhira T, Nishiyama O, Tabata Y. et al. A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung. Eur J Pharmacol 2020; 885: 173508
143 Matsuhira T, Nishiyama O, Tabata Y. et al. The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages. Biochem Biophys Rep 2021; 28: 101118
144 Richeldi L, Azuma A, Cottin V. et al; 1305-0013 Trial Investigators. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N Engl J Med 2022; 386 (23) 2178-2187
145 Helene M, Lake-Bullock V, Zhu J, Hao H, Cohen DA, Kaplan AM. T cell independence of bleomycin-induced pulmonary fibrosis. J Leukoc Biol 1999; 65 (02) 187-195
146 Schnell A, Littman DR, Kuchroo VKT. T_H17 cell heterogeneity and its role in tissue inflammation. Nat Immunol 2023; 24 (01) 19-29
147 Wilson MS, Madala SK, Ramalingam TR. et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010; 207 (03) 535-552
148 Mi S, Li Z, Yang HZ. et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol 2011; 187 (06) 3003-3014
149 Zhang J, Wang D, Wang L. et al. Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 2019; 316 (03) L487-L497
150 Celada LJ, Kropski JA, Herazo-Maya JD. et al. PD-1 up-regulation on CD4⁺ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production. Sci Transl Med 2018; 10 (460) eaar8356
151 Dikiy S, Rudensky AY. Principles of regulatory T cell function. Immunity 2023; 56 (02) 240-255
152 Liu Q, Dwyer GK, Zhao Y. et al. IL-33-mediated IL-13 secretion by ST2+ Tregs controls inflammation after lung injury. JCI Insight 2019; 4 (06) e123919
153 Okamoto M, Kuratani A, Okuzaki D. et al. Tff1-expressing Tregs in lung prevent exacerbation of bleomycin-induced pulmonary fibrosis. Front Immunol 2024; 15: 1440918
154 Farhat A, Radhouani M, Deckert F. et al. An aging bone marrow exacerbates lung fibrosis by fueling profibrotic macrophage persistence. Sci Immunol 2025; 10 (105) eadk5041
155 Kotsianidis I, Nakou E, Bouchliou I. et al. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179 (12) 1121-1130
156 Reilkoff RA, Peng H, Murray LA. et al. Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-β1-induced pulmonary fibrosis. Am J Respir Crit Care Med 2013; 187 (02) 180-188
157 Heitmann L, Rani R, Dawson L. et al. TGF-β-responsive myeloid cells suppress type 2 immunity and emphysematous pathology after hookworm infection. Am J Pathol 2012; 181 (03) 897-906
158 Walker JA, McKenzie ANJ. T_H2 cell development and function. Nat Rev Immunol 2018; 18 (02) 121-133
159 Gieseck III RL, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol 2018; 18 (01) 62-76
160 Vannella KM, Ramalingam TR, Borthwick LA. et al. Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven inflammation and fibrosis. Sci Transl Med 2016; 8 (337) 337ra65
161 Belperio JA, Dy M, Burdick MD. et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2002; 27 (04) 419-427
162 Singh B, Kasam RK, Sontake V, Wynn TA, Madala SK. Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2017; 313 (05) L796-L806
163 Karo-Atar D, Bordowitz A, Wand O. et al. A protective role for IL-13 receptor α 1 in bleomycin-induced pulmonary injury and repair. Mucosal Immunol 2016; 9 (01) 240-253
164 Izbicki G, Or R, Christensen TG. et al. Bleomycin-induced lung fibrosis in IL-4-overexpressing and knockout mice. Am J Physiol Lung Cell Mol Physiol 2002; 283 (05) L1110-L1116
165 Huaux F, Liu T, McGarry B, Ullenbruch M, Phan SH. Dual roles of IL-4 in lung injury and fibrosis. J Immunol 2003; 170 (04) 2083-2092
166 Park SW, Ahn MH, Jang HK. et al. Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function. J Korean Med Sci 2009; 24 (04) 614-620
167 Raghu G, Richeldi L, Crestani B. et al. SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). Eur Respir J 2018; 52 (06) 1801130
168 Maher TM, Costabel U, Glassberg MK. et al. Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. Eur Respir J 2021; 57 (02) 1902442
169 Parker JM, Glaspole IN, Lancaster LH. et al. A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2018; 197 (01) 94-103
170 Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37 (02) 356-363
171 Collard HR, Ryerson CJ, Corte TJ. et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 2016; 194 (03) 265-275
172 Ahangari F, Becker C, Foster DG. et al. Saracatinib, a selective Src kinase inhibitor, blocks fibrotic responses in preclinical models of pulmonary fibrosis. Am J Respir Crit Care Med 2022; 206 (12) 1463-1479
173 Pan L, Cheng Y, Yang W. et al. Nintedanib ameliorates bleomycin-induced pulmonary fibrosis, inflammation, apoptosis, and oxidative stress by modulating PI3K/Akt/mTOR pathway in mice. Inflammation 2023; 46 (04) 1531-1542
174 Decaris ML, Schaub JR, Chen C. et al. Dual inhibition of α_vβ₆ and α_vβ₁ reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res 2021; 22 (01) 265
175 Horan GS, Wood S, Ona V. et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008; 177 (01) 56-65
176 Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol 2022; 13: 838449